Restoring Safeguards for Dangerous Abortion Drugs Act
- Bill Number
- S. 1631
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-05-06: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Last Updated
- 2025-12-02T08:46:23Z
AI-Generated Summary
Purpose
This legislation, titled the "Restoring Safeguards for Dangerous Abortion Drugs Act," aims to reinstate stricter safety protocols for mifepristone (a medication used to end early pregnancies, also known as Mifeprex, Korlym, or RU-486). It seeks to revert risk management requirements to a previous standard, impose liability on certain providers for harms caused by illegally distributed versions of the drug, and prohibit its importation into the United States.
Key Provisions
- Risk Management Requirements (REMS):
- Within 90 days of enactment, the Secretary of Health and Human Services (HHS) must withdraw the current Risk Evaluation and Mitigation Strategy (REMS—a safety plan to monitor and limit risks of certain drugs) for mifepristone.
- HHS must then approve a new REMS identical to the one approved in June 2011.
- A REMS is permanently required for mifepristone, and no alternative version can be approved.
- Liability for Harms:
- Defines "covered entities" as telehealth providers (doctors or services offering remote consultations), pharmacies, or anyone who knowingly imports or transports mifepristone across state lines or international borders in violation of federal law (specifically, 18 U.S.C. § 1462, which prohibits mailing obscene or restricted materials).
- These entities are liable for any bodily injury or mental health harm (physical, psychological, emotional, or physiological) caused fully or partly by a patient's use of illegally imported or transported mifepristone.
- Affected individuals can sue covered entities in federal or state court for compensatory damages (to cover losses), punitive damages (to punish wrongdoing), and attorney's fees/costs.
- This provision does not override state laws providing other remedies and takes effect 90 days after enactment.
- Importation Ban:
- Amends Section 801 of the Federal Food, Drug, and Cosmetic Act to explicitly prohibit importing mifepristone into the U.S., including via mail, regardless of other laws allowing personal importation of drugs.
Significant Changes to Existing Law
- REMS Reversion: Reverses modifications to mifepristone's REMS made after 2011, which had loosened some restrictions (e.g., allowing prescriptions by non-physicians and mail delivery). This restores the original, more stringent 2011 requirements, such as in-person dispensing by certified providers.
- New Liability Framework: Introduces a federal private right of action (legal ability to sue) specifically targeting harms from illegally distributed mifepristone, which was not previously available under federal tort law for this drug.
- Importation Prohibition: Strengthens existing FDA import rules by adding an explicit, unconditional ban on mifepristone imports, closing potential loopholes for personal or mail-order shipments.
Potential Impacts
- On Government Agencies: HHS and the FDA will face mandatory timelines and restrictions on drug safety approvals, potentially increasing administrative burdens and limiting flexibility in future drug regulations. Enforcement of the importation ban may require additional resources from U.S. Customs and Border Protection.
- On Citizens: Women seeking medication abortions may face renewed barriers to access mifepristone through telehealth or mail, reverting to in-person clinic requirements. Those harmed by illegal versions could gain easier federal recourse for compensation, but legal challenges might arise in court.
- On International Relations: The import ban could strain relations with countries exporting pharmaceuticals, potentially affecting U.S. trade in generic drugs, though its scope is limited to this specific medication.
Main Stakeholders Affected
- Healthcare Providers and Pharmacies: Telehealth services and pharmacies distributing mifepristone risk liability for harms if involved in illegal transport/import, and must comply with the stricter 2011 REMS.
- Patients and Women: Primary users of mifepristone may experience reduced access options, while those harmed by unregulated sources gain new legal protections.
- Drug Manufacturers: Companies producing mifepristone (e.g., under brands like Mifeprex) must adhere to the reinstated REMS, potentially impacting distribution and sales.
- Government Entities: HHS/FDA for regulatory enforcement; courts for handling new lawsuits; federal law enforcement for import violations.
- Advocacy Groups: Pro-life organizations may support the safeguards, while reproductive rights groups could oppose access restrictions.
Notable Legal, Constitutional, or Political Implications
- Legal: Creates a targeted federal tort claim, which could lead to increased litigation and set precedents for drug-specific liability outside traditional product liability laws. The REMS mandate limits FDA discretion, potentially inviting challenges under the Administrative Procedure Act for being overly prescriptive.
- Constitutional: May raise questions about federal preemption of state abortion laws (though it explicitly avoids overriding state remedies) and interstate commerce regulation under the Commerce Clause. Access restrictions could indirectly intersect with reproductive rights debates post-Dobbs v. Jackson (2022 Supreme Court decision overturning federal abortion protections).
- Political: Reflects ongoing partisan divides on abortion policy, with the bill introduced by Sen. Hawley (R-MO) in a post-Roe landscape, likely facing opposition in a divided Congress and possible judicial review if enacted.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Recent Actions
- 2025-05-06: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2025-05-06: Introduced in Senate
Bill Versions
- Restoring Safeguards for Dangerous Abortion Drugs Act — issued 2025-05-06 — PDF (4 pages)